These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 22115131)

  • 1. Platinum anticancer drugs. From serendipity to rational design.
    Monneret C
    Ann Pharm Fr; 2011 Nov; 69(6):286-95. PubMed ID: 22115131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Satraplatin: BMS 182751, BMY 45594, JM 216.
    Drugs R D; 2007; 8(2):125-32. PubMed ID: 17324011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin.
    Kelland L
    Expert Opin Investig Drugs; 2007 Jul; 16(7):1009-21. PubMed ID: 17594186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity of platinum compounds.
    Hartmann JT; Lipp HP
    Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin: a review of preclinical and clinical studies.
    Raymond E; Chaney SG; Taamma A; Cvitkovic E
    Ann Oncol; 1998 Oct; 9(10):1053-71. PubMed ID: 9834817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
    Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
    Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
    Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
    Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
    Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
    Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The state-of-play and future of platinum drugs.
    Apps MG; Choi EH; Wheate NJ
    Endocr Relat Cancer; 2015 Aug; 22(4):R219-33. PubMed ID: 26113607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum compounds: a hope for future cancer chemotherapy.
    Ali I; Wani WA; Saleem K; Haque A
    Anticancer Agents Med Chem; 2013 Feb; 13(2):296-306. PubMed ID: 22583420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The status of platinum anticancer drugs in the clinic and in clinical trials.
    Wheate NJ; Walker S; Craig GE; Oun R
    Dalton Trans; 2010 Sep; 39(35):8113-27. PubMed ID: 20593091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Platinum compounds: metabolism, toxicity and supportive strategies].
    Lipp HP; Hartmann JT
    Praxis (Bern 1994); 2005 Feb; 94(6):187-98. PubMed ID: 15754530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Culy CR; Clemett D; Wiseman LR
    Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
    Monk BJ; Alberts DS; Burger RA; Fanta PT; Hallum AV; Hatch KD; Salmon SE
    Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro.
    Sooriyaarachchi M; Narendran A; Gailer J
    Metallomics; 2011 Jan; 3(1):49-55. PubMed ID: 21135941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
    Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
    J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies against prostate cancer--Pt(II)-based chemotherapy.
    Matos CS; de Carvalho AL; Lopes RP; Marques MP
    Curr Med Chem; 2012; 19(27):4678-87. PubMed ID: 22856665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.